Carola A Huber1, Matthias R Meyer2, Jan Steffel3, Eva Blozik4, Oliver Reich5, Thomas Rosemann6. 1. Department of Health Sciences, Helsana Group, Zürich, Switzerland. Electronic address: carola.huber@helsana.ch. 2. Institute of Primary Care, University of Zürich, University Hospital of Zürich, Zürich, Switzerland; Division of Cardiology, Triemli City Hospital, Zürich, Switzerland. 3. Department of Cardiology, University Hospital of Zürich, University Heart Center, Zürich, Switzerland. 4. Department of Health Sciences, Helsana Group, Zürich, Switzerland; Department of Medicine, University Medical Centre Freiburg, Freiburg, Germany. 5. Department of Health Sciences, Helsana Group, Zürich, Switzerland. 6. Institute of Primary Care, University of Zürich, University Hospital of Zürich, Zürich, Switzerland.
Abstract
PURPOSE: Secondary medication prevention after acute myocardial infarction (MI) is strongly recommended in international guidelines, but actual use, adherence, and outcomes in current clinical practice are largely unknown. Therefore, the aims of this study were to determine the current adherence to medications for secondary prevention after MI and to estimate the association between medication adherence and mortality and major adverse cardiovascular events (MACE) in a large real-world population. METHODS: Using a large health care claims database, patients were selected who had been hospitalized with MI between 2012 and 2015 (N = 4349). Adherence to drug therapy after discharge was measured as the medication possession rate (MPR) per year (0%-100%, indicating the number of days with medication supplied relative to the total number of days) for the individual drug classes. The relationship between MPR and the risk of MACE and death was assessed by using Cox proportional hazards regression models. FINDINGS: A high proportion of patients with low MPR (0%-79%) was observed for all drug classes (47.6% for dual antiplatelet therapy (DAPT), 23.5% for lipid-lowering drugs (LLDs), 47.3% for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and 88.1% for beta-blockers (BB). Women and elderly patients were less likely to receive LLDs. Patients with high adherence to DAPT, LLDs, and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (MPR ≥80%) had a significantly reduced risk for all-cause mortality and MACE (LLD-group). IMPLICATIONS: In a real-life setting, adherence to drug therapy for secondary cardiovascular prevention after MI was only moderate. Increased use of evidence-based treatment such as DAPT and LLDs in current clinical practice may improve long-term outcomes of patients with MI. Moreover, providing clear information, improved care transition, and a close collaboration between clinicians and physicians involved in an early outpatient follow-up is required.
PURPOSE: Secondary medication prevention after acute myocardial infarction (MI) is strongly recommended in international guidelines, but actual use, adherence, and outcomes in current clinical practice are largely unknown. Therefore, the aims of this study were to determine the current adherence to medications for secondary prevention after MI and to estimate the association between medication adherence and mortality and major adverse cardiovascular events (MACE) in a large real-world population. METHODS: Using a large health care claims database, patients were selected who had been hospitalized with MI between 2012 and 2015 (N = 4349). Adherence to drug therapy after discharge was measured as the medication possession rate (MPR) per year (0%-100%, indicating the number of days with medication supplied relative to the total number of days) for the individual drug classes. The relationship between MPR and the risk of MACE and death was assessed by using Cox proportional hazards regression models. FINDINGS: A high proportion of patients with low MPR (0%-79%) was observed for all drug classes (47.6% for dual antiplatelet therapy (DAPT), 23.5% for lipid-lowering drugs (LLDs), 47.3% for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and 88.1% for beta-blockers (BB). Women and elderly patients were less likely to receive LLDs. Patients with high adherence to DAPT, LLDs, and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (MPR ≥80%) had a significantly reduced risk for all-cause mortality and MACE (LLD-group). IMPLICATIONS: In a real-life setting, adherence to drug therapy for secondary cardiovascular prevention after MI was only moderate. Increased use of evidence-based treatment such as DAPT and LLDs in current clinical practice may improve long-term outcomes of patients with MI. Moreover, providing clear information, improved care transition, and a close collaboration between clinicians and physicians involved in an early outpatient follow-up is required.
Authors: Piotr Jankowski; Dariusz A Kosior; Paweł Sowa; Karolina Szóstak-Janiak; Paweł Kozieł; Agnieszka Krzykwa; Emilia Sawicka; Maciej Haberka; Małgorzata Setny; Karol Kamiński; Zbigniew Gąsior; Aldona Kubica; Dirk De Bacquer; Guy De Backer; Kornelia Kotseva; David Wood; Andrzej Pająk; Danuta Czarnecka Journal: Cardiol J Date: 2020-05-21 Impact factor: 2.737
Authors: Julian T Hertz; Francis M Sakita; Godfrey L Kweka; Tumsifu G Tarimo; Sumana Goli; Sainikitha Prattipati; Janet P Bettger; Nathan M Thielman; Gerald S Bloomfield Journal: Circ Cardiovasc Qual Outcomes Date: 2022-03-18
Authors: Carles Vilaplana-Carnerero; Ignacio Aznar-Lou; María Teresa Peñarrubia-María; Antoni Serrano-Blanco; Rita Fernández-Vergel; Dolors Petitbò-Antúnez; Montserrat Gil-Girbau; Marian March-Pujol; Juan Manuel Mendive; Alba Sánchez-Viñas; Cristina Carbonell-Duacastella; Maria Rubio-Valera Journal: Int J Environ Res Public Health Date: 2020-05-12 Impact factor: 3.390